Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation

BACKGROUND: Germline Checkpoint Kinase 2 gene (CHEK2) mutations can increase the risk of solid tumors. Recently, they have been identified as risk factors for hematologic malignancies. However, to the best of our knowledge, B-acute lymphoblastic leukemia (B-ALL) has never been described as a present...

Descripción completa

Detalles Bibliográficos
Autores principales: Ipe, Abraham, Angiolillo, Anne, Jacobsohn, David, Cheng, Jinjun, Bornhorst, Miriam, Turner, Joyce, Vatsayan, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014590/
https://www.ncbi.nlm.nih.gov/pubmed/36937957
http://dx.doi.org/10.3389/fped.2023.1067131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014590/
https://www.ncbi.nlm.nih.gov/pubmed/36937957
http://dx.doi.org/10.3389/fped.2023.1067131

Ejemplares similares